AAVXFNasdaqPharmaceutical PreparationsUS GAAP · USD

Abivax S.A.

Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in chronic inflammatory diseases. It is based in France and the United States and centers on advancing its lead drug candidate, obefazimod (ABX464), through late-stage clinical development.

Ask about the company
Revenue0.0m USD
Operating profit (EBIT)-302m USD
−84.2 %y/y
Net income-336m USD
−90.7 %y/y
Free cash flow-161m USD
−4.2 %y/y

Fiscal year 2025 · change from previous year

Development 2022–2025

-400-300-200-1000m USD2022: 0.00 m USD2022: EBIT -54 m USD20222023: 0.00 m USD2023: EBIT -134 m USD20232024: 0.00 m USD2024: EBIT -164 m USD20242025: 0.00 m USD2025: EBIT -302 m USD20250.00-302
RevenueOperating profit (EBIT)
Ask Clarifo about Abivax S.A.

Business

Share of revenue
Lead drug candidate100 %

Obefazimod and related development programs for inflammatory diseases.

Customers

Abivax does not sell commercial products broadly; its direct business counterparties are primarily clinical trial sites, contract research organizations, regulators, and development partners involved in advancing its drug candidates. The ultimate end customers, if approved, are patients with chronic inflammatory diseases such as ulcerative colitis. In practice, the company’s value proposition is tied to demonstrating clinical efficacy and safety that could support future pharmaceutical adoption.

Clinical development partners

CROs, investigators, labs, and manufacturers that execute the development program.

Regulatory stakeholders

Health authorities and ethics committees that assess trial data and approvals.

Patients with inflammatory disease

The intended end users of obefazimod if the therapy reaches commercialization.

Future healthcare payors

Insurers and public health systems that would reimburse treatment use after approval.

Strategy

Abivax’s strategy is centered on advancing obefazimod through late-stage clinical development in ulcerative colitis and building evidence for immune-modulating therapies in chronic inflammatory disease. The company’s competitive position depends on translating clinical data into regulatory progress and, ultimately, a differentiated therapeutic profile. It also maintains the financing and corporate infrastructure needed for a long development cycle.

Complete late-stage clinical developmentShort term

Clinical readouts are the main value driver for a single-asset biotech company.

Strengthen regulatory positioningShort term

Approval pathways depend on robust efficacy, safety, and quality data.

Preserve long-duration development capacityMedium term

Biotech development requires funding and operating flexibility over multiple years.

Geography

Abivax is headquartered in France with a U.S. presence and reports activity tied to both Europe and the United States. Its development operations are therefore exposed to transatlantic clinical, regulatory, and capital market requirements rather than a single national market. The company’s quoted listings in Paris and on Nasdaq also reflect that dual geographic footprint.

Risks

Abivax faces the typical risks of a clinical-stage biotech company: clinical failure, regulatory delays, and uncertainty around whether trial data will be strong enough for approval. Because its value is concentrated in a small number of programs, any setback in obefazimod or its inflammatory disease pipeline could materially affect the business.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Clinical development failure1Regulatory and approval risk4Financing and dilution risk2Pipeline concentration3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Clinical development failureImpact: CriticalLikelihood: Medium

    The company depends on obefazimod progressing successfully through late-stage trials.

    Exposure: Lead candidate in ulcerative colitis

  2. Financing and dilution riskImpact: HighLikelihood: High

    Clinical-stage companies often require repeated external capital before commercialization.

    Exposure: Research and development funding

  3. Pipeline concentrationImpact: HighLikelihood: High

    The company’s value is concentrated in a limited number of programs and indications.

    Exposure: Obefazimod and inflammatory disease pipeline

  4. Regulatory and approval riskImpact: HighLikelihood: Medium

    Regulators may request further data on efficacy, safety, or manufacturing quality.

    Exposure: Phase 3 and registration pathway

Ask Clarifo about Abivax S.A.

Accounting

Judgemental items
Research and development expense recognition

Clinical-stage biotech results are heavily affected by when trial and development costs are expensed.

Impact: Affects operating loss and comparability across periods

Fair value measurement of financing instruments

Borrowings, convertible notes, and derivatives may require valuation inputs and remeasurement.

Impact: Can create non-cash volatility in income and liabilities

Estimation uncertainty and judgments

Management must estimate fair values and other balance sheet items with limited observable data.

Impact: Can materially affect reported assets, liabilities, and expense timing

Liability derecognition under IFRS 9

The company adopted a policy change for certain electronic payment settlements.

Impact: Affects timing of liability removal and related financial statement presentation

Similar listed companies

Publicly listed companies with a comparable business focus.

AgomAb Therapeutics NV

AGMB · Biological Products, (No Diagnostic Substances)

Avalo Therapeutics, Inc.

AVTX · Pharmaceutical Preparations

BioLineRx Ltd.

BLRX · Pharmaceutical Preparations

Apogee Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)

AbbVie Inc.

ABBV · Pharmaceutical Preparations

Apimeds Pharmaceuticals US, Inc.

APUS · Pharmaceutical Preparations

Last updated: 28/09/2026